Revision history of "GENERIC DRUG IN COMBINATION OF AN ALPHA-BLOCKER AND AN ANTICHOLINERGIC FOR THE TREATMENT OF SYMPTOMS OF BENIGN PROSTATE HYPERPLASIA" (Q3173737)

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

9 October 2024

  • curprev 23:0023:00, 9 October 2024‎ DG Regio talk contribs‎ 62,425 bytes +10‎ ‎Changed label, description and/or aliases in pt
  • curprev 23:0023:00, 9 October 2024‎ DG Regio talk contribs‎ 62,415 bytes −43‎ ‎Set a claim value: summary (P836): This project raises the development of a new generic pharmaceutical speciality of tamsulosin-solifenacin, modified release tablets, at a dose of 0.4 mg tamsulosin and 6 mg solifenacin, for the treatment of filling and emptying symptoms associated with benign prostate hyperplasia (BPH)._x000D_ Currently no generic of this combination is registered on the Spanish market and the planned development will demonstrate its bioequivalence with the reference...

7 March 2024

20 December 2023

12 June 2023

10 June 2023

4 August 2022

  • curprev 10:4610:46, 4 August 2022‎ DG Regio talk contribs‎ 60,104 bytes +39,352‎ ‎Changed label, description and/or aliases in et, lt, hr, el, sk, fi, pl, hu, cs, lv, ga, sl, bg, mt, pt, da, ro, sv, nl, fr, de, it, es, and other parts: Adding translations: et, lt, hr, el, sk, fi, pl, hu, cs, lv, ga, sl, bg, mt, pt, da, ro, sv,

16 January 2022

17 December 2021

9 December 2021

4 December 2021

12 October 2021

  • curprev 21:2221:22, 12 October 2021‎ DG Regio talk contribs‎ 12,465 bytes +1,790‎ ‎Created claim: summary (P836): This project raises the development of a new generic pharmaceutical speciality of tamsulosin-solifenacin, modified release tablets, at a dose of 0.4 mg tamsulosin and 6 mg solifenacin, for the treatment of filling and emptying symptoms associated with benign prostate hyperplasia (BPH)._x000D_ Currently no generic of this combination is registered on the Spanish market and the planned development will demonstrate its bioequivalence with the refer...
  • curprev 21:2221:22, 12 October 2021‎ DG Regio talk contribs‎ 10,675 bytes −1,790‎ ‎Removed claim: summary (P836): This project raises the development of a new generic pharmaceutical speciality of tamsulosin-solifenacin, modified release tablets, at a dose of 0.4 mg tamsulosin and 6 mg solifenacin, for the treatment of filling and emptying symptoms associated with benign prostate hyperplasia (BPH)._x000D_ Currently no generic of this combination is registered on the Spanish market and the planned development will demonstrate its bioequivalence with the ref...
  • curprev 20:2820:28, 12 October 2021‎ DG Regio talk contribs‎ 12,465 bytes +191‎ ‎Changed label, description and/or aliases in en: translated_label
  • curprev 20:2820:28, 12 October 2021‎ DG Regio talk contribs‎ 12,274 bytes +1,790‎ ‎Created claim: summary (P836): This project raises the development of a new generic pharmaceutical speciality of tamsulosin-solifenacin, modified release tablets, at a dose of 0.4 mg tamsulosin and 6 mg solifenacin, for the treatment of filling and emptying symptoms associated with benign prostate hyperplasia (BPH)._x000D_ Currently no generic of this combination is registered on the Spanish market and the planned development will demonstrate its bioequivalence with the refer...

10 October 2021

9 October 2021

8 October 2021

Retrieved from "https://linkedopendata.eu/wiki/Item:Q3173737"